AF
PYXS icon

Avanza Fonder’s Pyxis Oncology PYXS Stock Holding History

Avanza Fonder’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,345
Closed -$31.4K – 505
2025
Q4 		$31.4K Buy
+27,345
New +$96.5K ﹤0.01% 494

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avanza Fonder's PYXS Position: Q1 2026 in Review

Avanza Fonder sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 27,345 shares — an estimated $31.4K sold.

Avanza Fonder first reported a position in PYXS in Q4 2025 and held it in 1 quarter. The position peaked at $31.4K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Avanza Fonder reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 27,345 Pyxis Oncology shares in Q1 2026, an estimated $31.4K.
  • Avanza Fonder first reported a position in Pyxis Oncology in Q4 2025 and held it in 1 quarter.
  • Avanza Fonder's Pyxis Oncology position peaked at $31.4K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.